Genetic alterations concerning the genes coding for cell cycle regulatory proteins have been described associated with B-chronic lymphoproliferative disorders. Most of them involve the pRb pathway and peculiarly the cyclin D1 protein that regulates the progression through the G1 phase and the G1 to S phase transition.
The 281 consecutive patients presented in this study were diagnosed in the same institution (Laboratoire d'Hé matologie, CHU Cô te de Nacre, Caen, France) on the basis of morphological and immunophenotypical criteria as proposed by the FAB group. The RT-PCR was adapted from Uchimaru et al, 3 and done as previously reported. products and an expression when this intensity was equivalent. Our results are presented in the Table 1 and illustrated in the Figures 1  and 2 . An over-expression of cyclin D1 mRNA was associated with MCL ( Figure 1, lanes 3, 6, 9 ), atypical B-CLL (Figure 1, lanes 5, 11) ; only a lower expression of cyclin D1 was revealed in HCL ( Figure 1 , lane 10). All patients expressed cyclin D3 and all but one (1 LLC) cyclin D2 (Figure 1) . When analyzed by Western blotting, cyclin D1 protein was detected in all cyclin D1 mRNA-expressing cells with various levels (Figure 2 ), also cyclin D2 as reported, 5 but never cyclin D3 except in the HCL (Figure 2, lanes 18, 21) . From our observations, we conclude that: (1) cyclin D1 protein is over-expressed in all MCL (23/23) tested, irrespective of the detection of t(11;14)(q13;q32) translocation. The competitive RT-PCR used here is a very sensitive mean to detect cyclin D1 gene transcription. The presence of cyclin D1 mRNA and protein appears as a real hallmark of MCL. The detection of cyclin D1 gene transcription should be considered of diagnostic value. (2) The vast majority of B-CLL does not express cyclin D1. The four B-CLL-expressing cyclin D1 protein are atypical. Despite morphological and immunophenotypical characteristics of CLL, they exhibit molecular features reminiscent of MCL such as high cyclin D1 mRNA content, low p27 KIP1 protein content (Figure 2 ), variable cyclindependent kinase-4 activity (Troussard et al, unpublished results) and therefore should be considered as a distinct subset of lymphoproliferative disorders. (3) The percentage of HCL expressing cyclin D1 is high (4/4 in this study). Considering the level of cyclin D1 mRNA, and of protein, only very sensitive techniques could detect such an expression. Thus, the percentage of HCL-expressing cyclin D1 is probably more important that reported in the literature. The activation of CCND1 locus is independent of the t(11;14)(q13;q32) translocation
Figure 1
Representative RT-PCR analysis. Peripheral blood lymphocytes were isolated from patient with B-LLC (lanes 2, 4, 7, 8), atypical B-LLC (lanes 5, 11), MCL (lanes 3, 6, 9), HCL (lane 10), and MM (lane 1). Total RNAs were purified and subjected to competitive RT-PCR. PCR products were separated on agarose gels, stained with ethidium bromide and compared to molecular weight markers (100 bp marker). Fragments corresponding to cyclin D1, cyclin D2 and cyclin D3 PCR products were 428 bp, 353 bp and 243 bp long, respectively.
Figure 2
Representative Western blot analysis. Peripheral blood cells from patients with B-CLL (lanes 1, 7, 14, 17, 19), cyclin D1-expressing B-CLL (lanes 11-13), MCL (lanes 2-6, 9, 10, 16, 20-22), HCL (lanes 8, 15, 18) were purified. Whole cell extracts were prepared according to Sola et al, 4 and proteins subjected to SDS-PAGE before being transferred on to Immobilon-P membranes and incubated with the following primary antibodies: polyclonal anti-cyclin D1 antibody (sc-718, Santa Cruz Biotech, Santa Cruz, CA, USA), polyclonal anti-cyclin D3 antibody (sc-182, Santa Cruz Biotech) and polyclonal anti-p27 antibody (sc-528, Santa Cruz Biotech). Blots were revealed with the ECL chemiluminescent system (Amersham Pharmacia Biotech, Freiburg, Germany). Leukemia t(11;14)(q13;q32). (4) The expression of cyclin D1 is a common event in MM (18/52, 35%). In order to assess the presence of t(11;14), FISH studies were done on five MM patients expressing cyclin D1, according to Avet-Loiseau et al. 6 In three out of five cases, we detected a t(11;14)(q13;q32) and, in the two others, extra copies of chromosome 11. Five MM patients with no cyclin D1 expression were also analyzed by FISH, we did not detect any chromosome 11 abnormalities. The prognostic value of cyclin D1 in MM remains to be evaluated.
Although, cyclin D2 and cyclin D3 mRNAs were ubiquitously expressed, in contrast with cyclin D2 protein, cyclin D3 protein was never present except in HCL. These findings indicate that some regulatory mechanisms still persist in tumor cells at a post-transcriptional level. In agreement with the study of Suzuki et al, 2 there is a selective expression of cyclin D in lymphoproliferative disorders, the significance of such phenomenon has to be studied. The finding of Ph chromosome in children suffering from ALL is closely associated with older age at presentation, a high leukocyte count, and high incidence of central nervous system leukemia. 1 The presence of BCR/ABL fusion in leukemic cells usually indicates highrisk leukemia warranting hemopoietic stem cell transplantation.
We report a new case of Ph+ ALL with two fusion BCR/ABL signals determined by FISH. The cytogenetic findings of additional chromosomal changes were precisely specified by using FISH, M-FISH and CGH methods.
A 5-year-old female presented with a 2-week history of hematoma, petechiae and epistaxis. Physical examination was remarkable for ecchymoses and scattered petechiae, but no lymphadenopathy or hepatomegaly. Initial laboratory results showed hemoglobin 104 g/l,
